Elizabeth Ofili

Learn More
Theresa M. Beckie, PhD; Cheryl Bushnell, MD, MHS, FAHA; Jeanine D’Armiento, MD, PhD; Penny M. Kris-Etherton, PhD, RD; Jing Fang, MD, MS; Theodore G. Ganiats, MD; Antoinette S. Gomes, MD; Clarisa R. Gracia, MD, MSCE; Constance K. Haan, MD, MS; Elizabeth A. Jackson, MD, MPH; Debra R. Judelson, MD; Ellie Kelepouris, MD, FAHA; Carl J. Lavie, MD; Anne Moore,(More)
IMPORTANCE Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preserved ejection fraction (HFPEF). OBJECTIVE To determine the effect of the phosphodiesterase-5 inhibitor sildenafil compared with placebo on exercise capacity and(More)
The authors' review of the health services literature since the release of the landmark Report of the Secretary's Task Force Report of Black and Minority Health in 1985 revealed significant differences in access to medical care by race and ethnicity within certain disease categories and types of health services. The differences are not explained by such(More)
BACKGROUND Ultrafiltration is an alternative strategy to diuretic therapy for the treatment of patients with acute decompensated heart failure. Little is known about the efficacy and safety of ultrafiltration in patients with acute decompensated heart failure complicated by persistent congestion and worsened renal function. METHODS We randomly assigned a(More)
BACKGROUND Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there are few prospective data to guide their use. METHODS In a prospective, double-blind, randomized trial, we assigned 308 patients with acute decompensated heart failure to receive furosemide administered intravenously by means of(More)
Janice G. Douglas, MD; George L. Bakris, MD; Murray Epstein, MD; Keith C. Ferdinand, MD; Carlos Ferrario, MD; John M. Flack, MD, MPH; Kenneth A. Jamerson, MD; Wendell E. Jones, MD; Julian Haywood, MD; Randall Maxey, MD; Elizabeth O. Ofili, MD; Elijah Saunders, MD; Ernesto L. Schiffrin, MD, PhD; Domenic A. Sica, MD; James R. Sowers, MD; Donald G. Vidt, MD;(More)
Distal coronary flow velocity measurements were previously limited to open heart or experimental procedures. Unlike previous Doppler catheter techniques, a Doppler angioplasty flow wire permits flow velocity measurements in both the proximal and distal segments of normal and diseased coronary arteries. In order to determine the potential clinical(More)
BACKGROUND AND OBJECTIVES Studies using Doppler catheters to assess blood flow velocity and vasodilator reserve in proximal coronary arteries have failed to demonstrate significant improvement immediately after coronary angioplasty. Measurement of blood flow velocity, flow reserve and phasic diastolic/systolic velocity ratio performed distal to a coronary(More)
OBJECTIVES This study was designed to assess whether the spectral waveform of coronary velocity on Doppler study is characteristically altered in the presence of significant stenosis with normalization of the spectral waveform after relief of endolumen obstruction. BACKGROUND Although coronary flow reserve determinations have provided physiologic(More)
BACKGROUND The role of eNOS gene polymorphisms on plasma nitrite or nitrate (NOx) level, endothelial function, and blood pressure (BP) remains unclear. METHODS We estimated the relationship of eNOS polymorphisms (the T(-786)C in the 5'-flanking promoter region, T(-786)C; 27-bp repeat in intron 4, eNOS4; and Glu298Asp in exon 7, G894T) with plasma NOx(More)